Search our Database of Scientific Publications and Authors

I’m looking for a
    Stereotactic Body Radiotherapy Results for Pulmonary Oligometastases: A Two-Institution Collaborative Investigation.
    Anticancer Res 2015 Sep;35(9):4903-8
    Department of Radiology, the University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.
    Aim: The current study investigated outcomes and prognostic factors of pulmonary oligometastases at two Institutions.

    Patients And Methods: SBRT (stereotactic body radiotherapy) as performed for pulmonary oligometastases from January 2004 to April 2014, and patients with a biologically effective dose (BED10) ≥ 75 Gy were registered in the study. Control of the primary tumor was not a criterion: we included both oligo-recurrence and sync-oligometastases.

    Results: A total of 34 patients were enrolled in the study. The median overall survival was 20 months (range=1-119 months) and the 2-year overall survival rate was 65.7% [95% confidence interval (CI)=48.3-83.1%]. The two-year local control rate was 79.1% (95% CI=62.4-95.8%). Stratified by oligo status, the 2-year overall survival rate of the oligo-recurrence group was 68.5% (95% CI=50.3-86.7%), while that of the group with sync-oligometastases was 50.0% (95% CI=1.0-99.0%). These rates were significantly different (p=0.037). No grade 5 early- or late-adverse events were recognized in the current study.

    Conclusion: SBRT for pulmonary oligometastases achieved good results and there was no serious adverse event. The oligo-recurrence group, in particular, achieved fairly good results.

    Similar Publications

    Lung stereotactic radiotherapy for oligometastases: comparison of oligo-recurrence and sync-oligometastases.
    Jpn J Clin Oncol 2016 Jul 9;46(7):687-91. Epub 2016 May 9.
    Department of Radiology, University of Tokyo Hospital, Tokyo.
    Background: Oligometastases can be divided into sync-oligometastases and oligo-recurrence. The difference is whether the primary site is uncontrolled or controlled. The goal of this multicenter study was to evaluate treatment outcomes and factors affecting survival after stereotactic body radiotherapy for pulmonary oligometastases. Read More
    A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases.
    Radiat Oncol 2012 Sep 27;7:164. Epub 2012 Sep 27.
    Radiation Therapy Department, Oscar Lambret Comprehensive Center Lille, 3 rue Combemale, Lille cedex, 59020, France.
    Purpose: The purpose of this study is to evaluate the feasibility, efficacy and toxicity of SBRT for treatment of unresectable hepatic or lung metastases regardless of their primary tumor site for patients who received prior systemic chemotherapy.

    Methods And Materials: Between July 2007 and June 2010, 90 patients were treated with the CyberKnife® SBRT system for hepatic or pulmonary metastatic lesions. Medical records were retrospectively reviewed. Read More
    Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.
    BMC Cancer 2016 Aug 19;16(1):659. Epub 2016 Aug 19.
    Department of Radiation Medicine, Hokkaido University Graduate School of Medicine, Kita 15-jo, Nishi 7-chome, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.
    Background: To investigate the prognostic value of oligo-recurrence in patients with brain-only oligometastases of non-small cell lung cancer (NSCLC) treated with stereotactic radiosurgery (SRS) or stereotactic radiotherapy (SRT).

    Methods: Patients treated with SRS or SRT for brain-only NSCLC oligometastases in 6 high-volume institutions in Japan between 1996 and 2008 were reviewed. Eligible patients met 1), 2), and 4) or 1), 3), and 4) of the following: 1) NSCLC with 1 to 4 brain metastases on magnetic resonance imaging (MRI) treated with SRS or SRT; 2) control of the primary lesions (thorax) at the time of SRS or SRT for brain metastases (patients meeting this criterion formed the oligo-recurrence group); 3) with SRS or SRT for brain metastases, concomitant treatment for active primary lesions (thorax) with curative surgery or curative stereotactic body radiotherapy (SBRT), or curative chemoradiotherapy (sync-oligometastases group); and 4) Karnofsky performance status (KPS) ≥70. Read More
    Dose Escalation Improves Outcome in Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Colorectal Cancer.
    Anticancer Res 2017 05;37(5):2709-2713
    Department of Radiation Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan.
    Aim: To evaluate the efficacy of stereotactic body radiotherapy (SBRT) for pulmonary metastasis from colorectal cancer.

    Patients And Methods: Data for 104 lesions from 93 patients who underwent SBRT for pulmonary oligometastases from colorectal cancer at ten Institutions were retrospectively analyzed. Toxicity was graded according to the Common Terminology Criteria for Adverse Events v4. Read More